iShares Core S&P Small-Cap

Most Recent

  • uploads///Tesla
    Consumer

    Is Tesla Bear Jim Chanos Buying Something New?

    Jim Chanos, the founder and president of Kynikos Associates, is a long-time short-seller of Tesla stock. Tesla stock has fallen 17.5% in the last year.

    By Rabindra Samanta
  • uploads///thermometer headache pain pills
    Company & Industry Overviews

    Aveo Pharmaceuticals Stock Fell More than 60% on January 31

    On January 31, Aveo Pharmaceuticals (AVEO) issued a press release announcing its decision not to file an NDA for Fotivda (tivozanib).

    By Margaret Patrick
  • uploads///light bulb _
    Company & Industry Overviews

    Why iRobot Stock Has Surged ~5% Today

    Today, iRobot (IRBT) stock surged 5.3% before the market opened.

    By Jitendra Parashar
  • uploads///Supernus
    Company & Industry Overviews

    A Financial Overview of Supernus Pharmaceuticals in September

    In Q2 2018, Supernus Pharmaceuticals (SUPN) reported net revenues of $99.5 million compared to $75.8 million in Q2 2017.

    By Daniel Collins
  • uploads///FTK Actual revenues
    Basic Materials

    Analyzing Flotek Industries’ 4Q17 Performance by Segment

    Flotek Industries (FTK) is 0.04% of the iShares Core S&P Small-Cap ETF (IJR). IJR increased 8% in the past year, versus a 56% decrease in FTK’s stock price during the period.

    By Alex Chamberlin
  • uploads///MDXG EPS Trend
    Company & Industry Overviews

    Behind MiMedx Group’s Recent Financial Performance

    In 3Q17, MiMedx Group’s (MDXG) net sales rose to $84.6 million, compared with $64.4 million in 3Q16—a 31% YoY (year-over-year) rise.

    By Kenneth Smith
  • uploads///Nektar Analysts Reco
    Company & Industry Overviews

    Analysts’ Ratings for Nektar Therapeutics in January 2018

    San Francisco–based biopharmaceutical company Nektar Therapeutics (NKTR) develops drug candidates that make use of its advanced polymer conjugate technology platforms.

    By Kenneth Smith
  • uploads///Analysts Ratings for Spectrum Pharmaceuticals
    Company & Industry Overviews

    Analysts’ Recommendations for Spectrum Pharmaceuticals

    Biotech firm Spectrum Pharmaceuticals (SPPI) develops oncology and hematology drug products. SPPI generates ~90% of its revenues from the US market, and ~10% of its revenues come from Europe.

    By Kenneth Smith
  • uploads///Graph
    Company & Industry Overviews

    Analyst Recommendations for Nektar Therapeutics in November 2017

    In 3Q17, Nektar Therapeutics (NKTR) reported revenues of $152.9 million, a YoY rise of 320.7%. The sudden spurt is mainly due to the upfront payment of $150 million from Eli Lilly.

    By Margaret Patrick
  • uploads///Part
    Company & Industry Overviews

    Analysts’ Recommendations for PetMed Express and Peers in 2017

    Of the five analysts covering PetMed Express (PETS) in October 2017, two gave it “strong buy” ratings, two gave it “hold” ratings, and one gave it a “sell” rating. Its target price was $43.75.

    By Kenneth Smith
  • uploads///Broker Recommendations
    Basic Materials

    Wall Street’s Forecast for Flotek Industries before Its 3Q17 Earnings

    On October 16, 2017, all analysts tracking Flotek Industries rated it as a “buy” or some equivalent.

    By Alex Chamberlin
  • uploads///Graph
    Company & Industry Overviews

    Analysts’ Recommendations for The Medicines Company in October

    In 2Q17, The Medicines Company (MDCO) reported revenues of $18.7 million, which is a fall of 66.0% on a YoY (year-over-year) basis.

    By Margaret Patrick
  • uploads/// Population over  US
    Company & Industry Overviews

    Why Structural Hurdles Could Thwart US Economic Progress

    The American economy is facing major structural issues that have the potential to thwart economic progress. The most important hurdle facing the US economy is an aging population.

    By Rick Rieder
  • uploads///Graph
    Company & Industry Overviews

    Ligand Pharmaceuticals Projects Higher Average Royalty Rate for Promacta

    Ligand Pharmaceuticals (LGND) receives royalties from Novartis on Promacta’s sales according to a tiered annual payment structure.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Analysts’ Recommendations for Ligand Pharmaceuticals and Peers in 2017

    In 2Q17, Ligand Pharmaceuticals (LGND) reported revenues of ~$28.0 million, representing year-over-year growth of ~43.4%. LGND received ~$14.2 million in royalties, a year-over-year rise of 45.7%.

    By Margaret Patrick
  • uploads///IV
    Basic Materials

    Flotek Industries’ Stock Price Forecast on August 10

    Flotek stock will likely close between $6.42 and $5.50 in the next seven days. Flotek’s stock price was $5.96 on August 10, 2017.

    By Alex Chamberlin
  • uploads///Net DEBT
    Basic Materials

    A Look at Flotek Industries’ Debt Position in 2Q17

    In 2Q17, Flotek Industries’ (FTK) total debt fell ~34% compared to 2Q16.

    By Alex Chamberlin
  • uploads///Stock Price and outlook
    Basic Materials

    What Could Drive Flotek Industries’ Growth?

    Flotek Industries’ (FTK) management expressed optimism about improving pricing for FTK’s complex nano-Fluid (or CnF) products despite higher raw material costs.

    By Alex Chamberlin
  • uploads///IV
    Miscellaneous

    What’s Flotek Industries’ Stock Price Forecast on July 3?

    On July 3, 2017, Flotek’s (FTK) implied volatility was ~58%. Since its 1Q17 earnings were announced on May 3, 2017, FTK’s implied volatility has remained unchanged.

    By Alex Chamberlin
  • uploads///Debt
    Miscellaneous

    Is Flotek’s Debt Rising or Falling?

    In 1Q17, Flotek Industries’ (FTK) total debt fell ~19% on a YoY basis. Its cash and marketable securities fell 26% during the same period.

    By Alex Chamberlin
  • uploads///Price and Outlook
    Miscellaneous

    Inside Flotek Industries’ Growth Drivers in 2Q17

    Flotek’s management expects an optimum recovery in energy reservoirs by upstream operators, which has already started to push demand for FTK’s technology.

    By Alex Chamberlin
  • uploads///SI
    Earnings Report

    Short Interest in Tidewater Fell: What Does It Mean?

    The short interest in Tidewater (TDW) stock as a percentage of its float was 27.6% as of January 18—compared to 37.3% as of September 30, 2016.

    By Alex Chamberlin
  • uploads///Stock Price and Managemetn Outlook
    Company & Industry Overviews

    What Are Flotek Industries’ Future Drivers?

    What does Flotek Industries’ management think? Flotek Industries’ (FTK) management believes the company resisted energy market weakness through steady performance in the energy chemistry segment. In the company’s 3Q16 conference call, Flotek Industries CEO John Chisholm stated that “we feel fortunate that our focus on high-end value added technology, especially in our energy chemistry segment […]

    By Alex Chamberlin
  • uploads///part__q
    Earnings Report

    Why Did H.B. Fuller’s Construction Products Revenue Fall?

    H.B. Fuller’s (FUL) Construction Products segment reported revenue of $64.4 million in 3Q16, which is 12.6% of the company’s total revenue.

    By Peter Neil
  • uploads///Net Debt to EBITDA
    Basic Materials

    Will Flotek Industries Reduce Its Debt?

    Flotek Industries’ net debt-to-trailing 12 month adjusted EBITDA (earnings before interest, tax, depreciation, and amortization) rose from 2Q15 to 2Q16.

    By Alex Chamberlin
  • uploads///Share Price and Projections
    Basic Materials

    What Are Flotek Industries’ Future Growth Drivers?

    Flotek Industries’ (FTK) management considers the current energy market environment to be challenging for the oilfield services industry.

    By Alex Chamberlin
  • uploads///annual revenue projections
    Company & Industry Overviews

    What Is Ligand Pharmaceuticals’s Expected Revenue Growth in 2016?

    Ligand Pharmaceuticals (LGND) is a high-growth company with a comparatively low-risk business model. It earns most of its revenue from royalty and license fees.

    By Jillian Dabney
  • uploads///
    Company & Industry Overviews

    Why Did Analysts Raise EBITDA Margin and EPS Estimates for Papa John’s?

    Analysts have revised their estimated EBITDA margins for Papa John’s (PZZA) for next four quarters.

    By Rajiv Nanjapla
  • uploads///Dos
    Company & Industry Overviews

    Investing Do’s and Don’ts from Richard Bernstein

    Richard Bernstein advises against trying to time the markets. What happens more often than not is that retail investors end up buying high and selling low—the opposite of what they should be doing.

    By David Ashworth
  • uploads/// US GDP
    Company & Industry Overviews

    Why Warren Buffett Strongly Believes in the American Dream

    Buffett said that it has been a terrible mistake to bet against America, not only for the past 240 years but even now. He believes that America’s emphasis on innovation and strength in commerce will continue to provide strong gains for its people.

    By Peter Barnes
  • uploads///C P FFO
    Company & Industry Overviews

    EdR’s Price-to-FFO Multiple Is Higher than Industry Average

    A closer look at EdR’s (EDR) trailing-12-month price-to-FFO multiple shows that it is in line with its historical valuation.

    By Peter Barnes
  • uploads///C PIC
    Company & Industry Overviews

    Investing in Education Realty Trust: A Must-Know Company Overview

    Education Realty Trust is a self-managed and self-administered equity REIT. The main objective of the company is to develop, acquire, own, and manage student housing properties.

    By Peter Barnes
  • uploads///last
    Earnings Report

    How Can Century Aluminum Manage the Current Downtrend?

    Fortunately for Century Aluminum, its leverage ratios are currently much lower than other companies in this space. CENX has $123 million in cash that should help it manage its operations over the next few quarters

    By Mohit Oberoi, CFA
  • uploads///part  shipments
    Earnings Report

    Why Century Aluminum’s Shipments Could Fall More

    Century Aluminum’s (CENX) consolidated shipments in 3Q15 were down 1% as compared to 2Q15. In 4Q14, CENX had acquired Alcoa’s stake in the Mt. Holly smelter.

    By Mohit Oberoi, CFA
  • uploads///Moving averages
    Macroeconomic Analysis

    What Are Analyst Recommendations for Vasco Data Security?

    Vasco Data Security (VDSI) has generated returns of -25.5% in the trailing 12 months and 3.0% in the trailing-one-month period.

    By Parker Thomas
  • uploads///part
    Earnings Report

    AK Steel’s 2Q15 Earnings and Outlook

    AK Steel (AKS) reported its 2Q15 earnings on July 28. The company’s share price rose significantly after it released its second quarter results.

    By Mohit Oberoi, CFA
  • uploads///World steel production
    Macroeconomic Analysis

    World Steel Production Declined in April

    According to data released on May 25 by the WSA, world crude steel production totaled 135 million tons in April. This is a decline of 1.7% YoY.

    By Anuradha Garg
  • uploads///part
    Macroeconomic Analysis

    Is the Steel Industry Gaining Strength?

    This year, steel companies have had a mixed performance on Wall Street. However, there are signs of a revival in the steel industry.

    By Mohit Oberoi, CFA
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.